UK real-world data of radium-223 dichloride in metastatic prostate cancer

Manreet Randhawa(Beatson West of Scotland Cancer Centre), Neil McPhail(Cancer Research UK), Angus Robinson(Royal Sussex County Hospital), Gail Buchanan(Beatson West of Scotland Cancer Centre), John McGrane(Royal Cornwall Hospital), David Bottomley(San Antonio College), Robert J. Jones(Beatson West of Scotland Cancer Centre), Joe M. O’Sullivan(San Antonio College), G. M. RACE(University of Southampton), Loretta Sweeney(Velindre Cancer Centre), Amarnath Challapalli(NIHR Bristol Biomedical Research Centre), Santhanam Sundar(Nottingham University Hospitals NHS Trust), Vincent Khoo(The University of Texas MD Anderson Cancer Center), Xue Jiang(Freeman Hospital), Irene Stratton(Cheltenham General Hospital), Robert B. Stevenson(Queen Elizabeth Hospital Birmingham), John Logue(San Antonio College), Duncan B. McLaren(NHS Lothian), Danish Mazhar(University of Cambridge)
Nuclear Medicine Communications
October 15, 2025
10.1097/mnm.0000000000002050
Cited by 1

Related Papers

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k